Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AKBAthis companyAkebia Therapeutics, Inc.	$0.51	-77.4×	12.7×	1.75×	20.5×	-604.2%	83.3%	9.9%	-2.3%	-16.4%	9.3%	16.4%	6.63×	1.45×	0.97×	1.13×	0.0%	3	-5.78	1	D+
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
CRVSCorvus Pharmaceuticals, Inc.	$11.10	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
FDMT4D Molecular Therapeutics, Inc.	$12.43	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
GOSSGossamer Bio, Inc.	$11.42	-4.16×	-5.77×	14.62×	-5.51×	1153.6%	97.9%	-336.8%	-351.5%	138.8%	-148.7%	-24.2%	-1.65×	-1.04×	-14.86×	2.64×	0.0%	3	-35.69	2	C+
OLMAOlema Pharmaceuticals, Inc.	$7.24	-13.37×	4.55×	0×	-13.14×	-93.1%	0.0%	0.0%	0.0%	-33.9%	-37.0%	-6.7%	0×	0.29×	0×	9.95×	0.0%	2	4.21	2	C+
Peer median	—	-12.79×	4.3×	0×	-12.7×	-93.1%	0.0%	0.0%	0.0%	-27.7%	-37.0%	-6.7%	0.02×	0.29×	0×	9.39×	0.0%	3	1.71	2	—